NICE

Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.

[NICE @NICEComms]

Thousands of people living with a chronic liver condition are set to benefit from a new daily pill that tackles both the disease itself and the persistent, severe itching it causes.

Find out more about seladelpar: https://t.co/ZOklHdwxLR

[NICE @NICEComms]

NICE has recommended mirvetuximab soravtansine for NHS patients with platinum-resistant ovarian cancer.

The first new treatment recommended for this condition in over 20 years.

Learn more: https://t.co/o1YXNTehIr

[NICE @NICEComms]

The first immunotherapy for people with an aggressive form of stomach cancer has been recommended in final guidance published today.

Durvalumab is recommended for over 1,500 people a year: https://t.co/lrwEKs6mhz

[NICE @NICEComms]

Around 670 people living with a serious type of high blood pressure that affects the lungs can now benefit from a new treatment option.

Read our guidance on sotatercept for treating pulmonary arterial hypertension here:
https://t.co/jBROj1du9b

[NICE @NICEComms]

Women with type 1 diabetes who are pregnant or planning a baby should be offered a pregnancy-specific 'artificial pancreas' device.

It automatically monitors blood sugar and delivers insulin, reducing the need for regular finger prick tests.

Read more: https://t.co/HZuLfchFgs

[NICE @NICEComms]

Pleased to be working with @CVDPREVENTaudit on this important collaboration.

[CVDPREVENT @CVDPREVENTaudit]

‍The CVDPREVENT Audit is pleased to announce a new collaboration agreement with the National Institute for Health and Care Excellence, marking a key step forward in strengthening cardiovascular disease prevention across healthcare systems in England. @NICEComms #NICE #CVDPREVENT

[NICE @NICEComms]

No two products are the same, so no two NICE Advice projects should be either. Andrew Walsh explains how our NICE Advice service builds flexibility into everything it does and why the right approach always starts with a conversation. 💡🔗 https://t.co/0st6VsFRim

[NICE @NICEComms]

We're at #NHSConfed2026 next week!

Catch our experts on two day 1 panels: medicines policy in the new NHS operating model, and getting innovation from research to real-world adoption.

Find us at stand B19.

[NICE @NICEComms]

Health and care professionals, stay updated with NICE's latest guidelines via our WhatsApp updates channel.

📱On mobile? Join here: https://t.co/xxeOwkx9RB

🖥️On desktop? Scan the QR code in the video.

🔔Once subscribed hit the bell to stay notified.

[NICE @NICEComms]

View NICE's priority topics for 2026-27 here: https://t.co/mJOAahVvdZ

[NICE @NICEComms]

Our forward view sets out the areas we will prioritise each year.

This year we’ve added a new section highlights the strategic areas we’ll be focusing on in guidance development, such as:

✅the 10 Year Health Plan
✅the modern service frameworks
✅biosimilars and generics

[NICE @NICEComms]

Just over 1,100 people with an aggressive form of lung cancer could be set to benefit after we recommended a new medicine in final draft guidance published today.

Find out more about serplulimab: https://t.co/irdu8RykDe

[NICE @NICEComms]

When a medicine's patent expires, lower-cost versions called biosimilars can be developed. A new taskforce is aligning regulation and NHS commissioning to speed up patient access.

John Spoors and Danielle Lees, explain more: https://t.co/M3XCPjgGc8

[NICE @NICEComms]

Our positive guidance recommendation has also been welcomed by @NHSEngland’s national clinical director for respiratory disease.

[NICE @NICEComms]

Thousands of people with COPD could be set to benefit from a new targeted treatment recommended in final draft guidance today.

Find out more about mepolizumab: https://t.co/BKoeYGCh4a

[NICE @NICEComms]

The chief executive of @asthmalunguk said today’s announcement could help thousands access a life-changing treatment.

[NICE @NICEComms]

⏰Webinar starting soon.

NICE is consulting on a new approach to managing funding variation requests, join John Spoors and the funding variation taskforce to hear more about the proposals.

Watch here: https://t.co/xylJdaftAQ

[NICE @NICEComms]

We've updated our guidance on what should happen after someone is treated for a severe allergic reaction (anaphylaxis) in A&E.

Some patients can now go home sooner if it's safe to do so, with an adrenaline pen and clear advice.

Read more: https://t.co/xtzt9Gn0je
@ResusCouncilUK

[NICE @NICEComms]

Thousands of people with advanced lung cancer now have a new treatment option on the NHS in England.

We've recommended cemiplimab with chemotherapy for adults with untreated non-small-cell lung cancer.

Find out more: https://t.co/ZhyfOxsUd3

[NICE @NICEComms]

“It has restored my life.”

Joanne had suffered from migraines for a decade. Since being prescribed a new tablet recommended by NICE, she hasn't had a single attack.

She's one of more than 20,000 people already benefitting.

Explore our data story: https://t.co/aPiKaClbx8